Stock Performance and Market Context
On 28 August 2026, Gujarat Kidney & Super Speciality Ltd’s stock surged by 4.58% to close near its 52-week high, registering an intraday peak of Rs 161.55. This marks a notable outperformance against the broader Sensex, which recorded a modest gain of 0.26% on the same day. The stock has been on a positive trajectory, gaining 5.81% over the past two days and outperforming its hospital sector peers by 3.87% today.
The company’s market capitalisation remains in the micro-cap segment, with a Mojo Score of 62.0 and a current Mojo Grade of Hold, reflecting a recent downgrade from Buy on 24 August 2026. Despite this, the stock’s upward momentum is evident as it trades above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained investor confidence in the near term.
Comparative Returns and Historical Context
Examining Gujarat Kidney & Super Speciality Ltd’s returns over various time frames highlights its relative strength. Year-to-date, the stock has surged by 56.64%, significantly outpacing the Sensex’s decline of 9.49%. Over the past month, the stock delivered a remarkable 26.73% gain, compared to the Sensex’s modest 0.48% rise. Even over three months, the stock’s 17.70% return dwarfs the Sensex’s 1.67% increase.
While the stock’s one-year, three-year, five-year, and ten-year returns are recorded as 0.00%, this is likely due to data unavailability rather than performance absence. The Sensex, by contrast, has posted positive returns over these longer periods, with a 10-year gain of 177.65%. The recent strong performance of Gujarat Kidney & Super Speciality Ltd underscores its growing prominence within the hospital sector.
Valuation Metrics and Financial Ratios
At the current price of Rs 160.95, the stock trades at a price-to-earnings (P/E) ratio of 77 times trailing twelve months earnings, indicating a premium valuation relative to earnings. The price-to-book value stands at 4.81 times, while enterprise value multiples include EV/EBITDA at 44.03 times and EV/EBIT at 53.34 times. These elevated multiples reflect investor expectations for the company’s growth and profitability within the hospital industry.
Dividend metrics are not available, with no recent dividend payout or yield reported. The stock’s 52-week range spans from Rs 98.25 to Rs 163.05, with the current price just 1.29% below the 52-week high, underscoring the recent rally’s strength.
Technical Analysis and Market Sentiment
The technical trend for Gujarat Kidney & Super Speciality Ltd is mildly bullish, having shifted from a bullish stance on 24 August 2026 at a price of Rs 152.60. Key technical indicators provide a mixed but generally positive outlook: the MACD and Bollinger Bands signal bullish momentum, while the Relative Strength Index (RSI) shows no clear signal. Dow Theory indicates a bullish trend on the monthly timeframe, supported by the KST and On-Balance Volume (OBV) indicators.
Immediate support is identified at the 52-week low of Rs 98.25, while resistance levels include Rs 142.20 (20-day moving average) and Rs 130.32 (100-day moving average). The stock is approaching its major resistance at the 52-week high of Rs 163.05, which it nearly touched during intraday trading.
Delivery Volumes and Trading Activity
Trading volumes have shown a marked increase, with delivery volumes rising by 121.75% over the past month. On 27 August 2026, delivery volume reached 2.96 lakh shares, representing 58.92% of total volume, significantly higher than the five-day average of 2.78 lakh shares and the trailing one-month average of 2.84 lakh shares. This heightened activity suggests strong participation from shareholders and traders alike.
Quality Assessment and Financial Health
Gujarat Kidney & Super Speciality Ltd’s quality assessment reflects a company with excellent growth prospects and a robust capital structure. The management risk is rated as average, while growth and capital structure receive excellent marks. The company maintains a low debt profile, with an average debt to EBITDA ratio of 0.92 and net debt to equity at zero, indicating minimal leverage.
Return on capital employed (ROCE) is strong at 26.45%, signalling efficient use of capital to generate earnings. However, return on equity (ROE) is currently weak at zero, which may be influenced by accounting or structural factors. The company has no promoter share pledging and low institutional holdings at 5.44%, reflecting a stable ownership base.
Recent Financial Trends
Short-term financial trends are positive, with net sales for the nine months ending June 2026 reported at ₹88.12 crores, higher than previous periods. Profit after tax (PAT) for the same period rose to ₹13.16 crores. Quarterly profit before tax excluding other income stood at ₹6.27 crores, marking a 23.1% increase compared to the previous four-quarter average. These figures demonstrate the company’s ability to sustain growth and profitability in a competitive sector.
Conclusion
The attainment of an all-time high price by Gujarat Kidney & Super Speciality Ltd on 28 August 2026 is a testament to its solid financial performance, favourable technical indicators, and strong market positioning within the hospital sector. While valuation multiples suggest a premium, the company’s growth metrics, quality assessment, and recent financial results provide a comprehensive picture of a firm that has steadily advanced to this milestone. The stock’s sustained gains and robust trading volumes further underscore its current market strength.
